2+ has a well-recognized role as an essential cofactor for all ATP-binding enzymes, its role as a signaling ion, like Ca 2+ , has been controversial. A requirement for Mg 2+ for optimal T lymphocyte stimulation was demonstrated more than 30 years ago, but the mechanism of its synergistic effect with Ca 2+ in T cell activation remains elusive. Here, we summarize our recent discovery of a signaling role for Mg 2+ in the T cell antigen receptor (TCR) signaling pathway from the study of a novel primary immunodeficiency, now named X-linked immunodeficiency with Mg 2+ defect, EBV infection and neoplasia (XMEN). XMEN patients were found to have a deficiency in magnesium transporter 1 (MAGT1), an Mg 2+ -specific transporter, which leads to the absence of a TCR-stimulated Mg 2+ flux and an attenuation of T cell activation. We further showed that this Mg 2+ flux is required proximally for the temporal orchestration of phospholipase C-␥1 (PLC␥1) activation. Thus, our study not only provides a second messenger role for Mg 2+ to explain its synergism with calcium in T cell signaling, it also identifies a potential extracellular therapeutic target for T cell-specific immunomodulation.
Mg
2+ is the most abundant, divalent cation in mammalian cells. Although, cells exhibit high concentrations of intracellular Mg 2+ (10-30 mM), most of it is bound to proteins, phospholipids, nucleic acids, and particularly ATP [1] [2] [3] . However, the free cytosolic Mg 2+ (0. only 1-5 % of the total Mg 2+ , and is actively maintained at 50 to 100-fold lower than its electrochemical equilibrium potential [4] . Unlike Ca 2+ , the role of Mg 2+ as a second messenger remains controversial [5] . Nevertheless, over the last thirty years, an increasing number of observations have been reported that implicate Mg 2+ in various cell functions in response to extracellular stimuli [6, 7] . For example, the role of intracellular, free Mg 2+ in growth factor-induced cell proliferation, originally thought to be strictly a co-factor effect, has been re-evaluated as a possible second messenger role [8] . In the immune system, several studies have shown that extracellular Mg 2+ acts synergistically with Ca 2+ in T cell activation, but not in B cells stimulated with lipopolysaccharide (LPS) [9] [10] [11] . Moreover, in suboptimal extracellular concentrations of Ca 2+ , extracellular Mg 2+ is able to restore interleukin-2 (IL-2) receptor expression and cell proliferation in T cells stimulated by phytohemagglutinin (PHA), but not by ionomycin [12] . As ionomycin is a Ca 2+ ionophore that bypasses proximal T cell receptor (TCR) signaling events to induce Ca 2+ signaling, this result suggests that optimal T cell activation requires a Mg 2+ -dependent process upstream of the Ca 2+ flux induction. In all these cases, the mechanism of action of the Mg 2+ as a signaling ion remains elusive.
Recently, we reported a novel primary immunodeficiency named X-linked immunodeficiency with magnesium defect, EBV infection and neoplasia (XMEN) [13] . Our work unraveled a signaling role for Mg 2+ in TCR signaling by identifying the loss of the Mg 2+ transporter MAGT1 as the cause of this disease. This study demonstrated that TCR stimulation induced an Mg 2+ flux through MAGT1 that was important for the activation of PLC␥1 and its downstream effects, including the production of inositol triphosphate (IP3) and the consequent release of Ca 2+ .
Description of patients and the TCR defect
Our study began with two young boys (patient A.1 and A.2) with a history of recurrent viral infections including chronic, active Epstein-Barr virus (EBV) infections. These patients exhibited low CD4 + T cells counts, leading to an inverted CD4:CD8 ratio. Other lymphocyte populations did not show any major disturbances. We first ruled out well-established causes of low CD4 + T cells counts, such as infections with human immunodeficiency virus (HIV) or cytomegalovirus (CMV), bare lymphocyte syndrome, Wiskott-Aldrich syndrome, and Di-George syndrome. Then we assessed the CD31 + cell population amongst the CD4 + CD27 + CD45RO -naïve T cells and found this population reduced in the patients compared to normal controls, indicating a diminished thymic output of CD4 + T cells.
We assessed T cell function by testing the ability of the patients' T cells to activate normally upon TCR engagement using an agonist anti-CD3 antibody (OKT3). We found that patients' T cells exhibited defective induction of several activation markers, such as CD69, CD25, Fas (CD95) and CTLA-4, in response to TCR stimulation ( figure 1A ). Looking at earlier signaling events, we observed that TCR-induced translocation of essential transcription factors, such as NF-B and NFAT, was also impaired in the patients' cells ( figure 1B) . However, these defects were rescued by using the second messenger inducers phorbol 12-myristate 13-acetate (PMA) and ionomycin, showing that the patients had a proximal TCR signaling defect prior to the induction of the Ca 
Characterization of the genetic defect
As the two patients were brothers, we hypothesized that the defect could be X-linked. To assess this possibility we tested for random lionization or inactivation of each of the mother's X chromosomes [14] . If one of the X chromosomes carries a genetic mutation conferring a selective disadvantage to the cell (e.g. impacting proliferation or survival), then skewed lyonization reflects the loss of cells with an active X chromosome carrying the mutation. Based on this hypothesis, we performed a lyonization assay and showed that the mother's T cells exhibited inactivation of only one of her X chromosomes instead of the expected random inactivation of both X chromosomes. This skewed lyonization led us to search for a genetic defect on the X chromosome. We performed X chromosome exon-capture and single-end Solexa sequencing on genomic DNA from the mother and the two boys. According to our X-linked genetic model with skewed lyonization in the mother, we hypothesized that the defect should be present in both brothers, heterozygous in the mother, and not present in the mother's cDNA. Using these criteria, we initiated the analysis by looking for single nucleotide polymorphisms (SNPs) or 1-2 bp deletion-insertion polymorphisms (DIPs). We found no nonsense mutations or 1-2 bp DIPS. DIPs larger than 2 bp are not revealed by singleend Illumina sequencing, so we ruled out large S110 MAGT1 in T cell signaling DIPs (>1,000 bp) using a comparative genomic hybridization array. For the intermediate DIPs (3-1,000 bp), we searched for missing coverage in the patients, but not in the mother, by developing a new computational tool. This approach allowed us to identify a 10 bp deletion present in both patients in MAGT1, a gene coding for a Mg 2+ transporter. Consistent with our genetic model, the deletion was not found in the mother's cDNA or in 100 normal controls. Finally, we confirmed the presence of the deletion by Sanger sequencing in both patients and showed it was heterozygous in the mother's genomic DNA. Moreover, this mutation was also carried by the grandmother and the great-grandmother of the patients. The deletion was located in the 3' exon-intron junction of the exon 7 of MAGT1 and induced the splicing of exon 6 with exon 9, creating a premature stop codon. This early termination led to a decrease of MAGT1 mRNA of ≈80 % by nonsense-mediated decay leading to the loss of MAGT1 protein expression in the patients. To link the TCR-activation defect and the loss of MAGT1 in the patients, we looked to see how TCR stimulation with an OKT3 antibody affected free Mg 2+ level in T cells. Interestingly, we showed that TCR stimulation induced an Mg 2+ flux in normal T cells, which was impaired in patients' cells even with high doses of agonist ( figure 1C) . Moreover, the TCR-induced Ca 2+ flux was drastically decreased in the patients' T cells, raising the possibility that the Ca 2+ flux was dependent on Mg 2+ ( figure 1C 2+ flux was, at least partially needed for the induction of the Ca 2+ flux, but not the converse. Moreover, we found that the BCR stimulation did not induce an Mg 2+ flux, which is consistent with the fact that B cell activation was normal in the patients.
MAGT1 deficiency impairs TCR-induced
We were able to impair the TCR-induced Mg 2+ flux as well as NF-B translocation by knocking down MGAT1 in normal T cells, mimicking the patients' phenotype. We also rescued patients' T cells with ectopic expression of MAGT1, restoring the TCR-induced Mg 2+ flux and the upregulation of activation markers upon TCR stimulation. These results established that MAGT1 mediated the Mg 2+ influx required for full T cell activation. Thus, MAGT1 deficiency was the probable cause of the cellular defect in XMEN disease.
Impairment of PLC␥1 activation in MAGT1-deficient patients
Since we showed that the Mg 2+ flux was necessary to induce a full Ca 2+ response, we next wanted to examine the TCR signaling event leading to the generation of the Ca 2+ flux [17, 18] . Stimulation of the TCR induces the activation of the Lck kinase, which initiates a cascade of phosphorylation events leading to the activation of the PLC␥1 that generates diacylglycerol (DAG) and IP3 (figure 2). IP3 then triggers the release of the Ca 2+ from the endoplasmic reticulum initiating the store-operated calcium entry (SOCE), which is the Ca 2+ flux induced by TCR. By assessing the phosphorylation status of the different components of the TCR signaling apparatus, we showed that the phosphorylation of PLC␥1 was delayed in patient cells after TCR stimulation. Indeed, the peak of phosphorylation of PLC␥1 induced by OKT3 stimulation was shifted from five minutes in normal control T cells to 60 minutes in patient cells. As IP3 production was also delayed, we determined that PLC␥1 activation was the proximal step regulated by Mg 2+ . Thus, our findings suggested that Mg 2+ acts as a second messenger in TCR signaling, leading to the activation of PLC␥1.
Conclusion

Mg
2+ plays a central role in many cellular functions by acting as a cofactor for all ATP-consuming enzymes as well as a stabilizer for structural membrane phospholipids [19, 20] . However, our data showed that a transient, Mg 2+ influx mediated by MAGT1 after TCR stimulation was able to modulate the activation of PLC␥1, and the subsequent Ca 2+ influx. These observations revealed an essential role for Mg 2+ in the TCR signaling. A study of XMEN patients also revealed that their lymphocytes exhibited a defective Mg 2+ uptake leading to lower basal levels of free Mg 2+ . However, this could not account for defective T cell activation, as the patients' B cells activated normally compared to controls. Recently, the role of TRPM7 in Mg 2+ homeostasis in B cells has been described, and a lack of TRPM7 can be compensated for by overexpressing MAGT1 in the B cell line [21] . These observations, taken together with ours, make us think that TRPM7 may play S112 MAGT1 in T cell signaling 
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